0001104659-03-006423.txt : 20030414 0001104659-03-006423.hdr.sgml : 20030414 20030414171500 ACCESSION NUMBER: 0001104659-03-006423 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20030414 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDICALCV INC CENTRAL INDEX KEY: 0001144284 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 411717208 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-62263 FILM NUMBER: 03649116 BUSINESS ADDRESS: STREET 1: 9725 SOUTH ROBERT TRAIL CITY: INVER GROVE HEIGHTS STATE: MN ZIP: 55077 BUSINESS PHONE: 6514523000 MAIL ADDRESS: STREET 1: 9725 SOUTH ROBERT TRAIL CITY: INVER GROVE HEIGHTS STATE: MN ZIP: 55077 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MILLER PAUL K CENTRAL INDEX KEY: 0000946863 IRS NUMBER: 477142088 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 1809 LYDIA AVE CITY: ST PAUL STATE: MN ZIP: 55113 BUSINESS PHONE: 6516530968 MAIL ADDRESS: STREET 1: 1809 LYDIA AVE EAST CITY: ROSEVILLE STATE: MI ZIP: 55113 SC 13D/A 1 j9438_sc13da.htm SC 13D/A

SEC 1746
(11-02)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

	UNITED STATES	OMB APPROVAL
	SECURITIES AND EXCHANGE COMMISSION	OMB Number: 3235-0145
	Washington, D.C. 20549	Expires: December 31, 2005
	SCHEDULE 13D	Estimated average burden hours per response. . 11

INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS
THERETO FILED PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

MedicalCV, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

584639 10 8

(CUSIP Number)

Paul K. Miller
1809 Lydia Avenue
St. Paul, Minnesota 55113
(651) 636-8968

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

April 4, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

CUSIP No. 584639 10 8

	1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Paul K. Miller

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)			[ ]
		(b)			[ ]

	3.	SEC Use Only

	4.	Source of Funds (See Instructions) PF, OO

	5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ]

	6.	Citizenship or Place of Organization Minnesota

Number of Shares Beneficially Owned by Each Reporting Person With			7.	Sole Voting Power 2,515,580*

			8.	Shared Voting Power 9,000**

			9.	Sole Dispositive Power 2,515,580*

			10.	Shared Dispositive Power 9,000**

	11.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,524,580

	12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]

	13.	Percent of Class Represented by Amount in Row (11) 28.8%

	14.	Type of Reporting Person (See Instructions) IN

* Represents (a) 1,367,580 shares of common stock, (b) 100,000 units, each consisting of one share of common stock and one redeemable Class A Warrant to purchase one share of common stock, (c) 100,000 shares of common stock purchasable upon the exercise of warrants, (d) 28,000 shares of common stock purchasable upon the exercise of options, (e) 700,000 shares of common stock purchasable by PKM Properties, LLC, an entity owned by the reporting person, upon the exercise of warrants, and (f) 120,000 shares of common stock owned by Gracon Contracting, Inc., an entity owned by the reporting person.

** Represents 4,500 units, each consisting of one share of common stock and one redeemable Class A Warrant to purchase one share of common stock, owned by the reporting person's spouse.

Paul K. Miller (the "Reporting Person") hereby amends his statement on Schedule 13D (the "Schedule 13D") originally filed on November 27, 2001, as amended on November 30, 2001, with respect to his beneficial ownership of shares of common stock, par value $0.01 per share, of MedicalCV, Inc., a Minnesota corporation ("MCV"). Item 3, Item 5 and Item 7 of the Schedule 13D are hereby amended and restated to read as follows:


Item 3.	Source and Amount of Funds or Other Consideration
On January 17, 2003, MCV entered into a discretionary credit agreement with PKM Properties, LLC ("PKM"), an entity owned by the Reporting Person, covering advances by PKM of up to $943,666, secured by MCV's assets. This facility was subsequently increased to $1,243,666. In consideration of such extension of credit, MCV agreed to issue to PKM a five-year warrant for the purchase of 350,000 shares of common stock at an exercise price of $0.596 per share. Issuance of the warrant was subject to approval by MCV's shareholders. Following the delisting of MCV's securities from The Nasdaq SmallCap Market on March 17, 2003, this warrant was issued without shareholder approval, effective January 17, 2003.
On April 4, 2003, MCV completed a refinancing transaction in which its facilities located at 9725 South Robert Trail, Inver Grove Heights, Minnesota, were sold in a sale-leaseback transaction to PKM. Mr. Miller is a director of MCV and is its largest beneficial owner of securities. The aggregate consideration for the sale was $3.84 million, paid in cash of $1.0 million, and by PKM’s assumption of MCV’s $2.5 million indebtedness to Associated Bank Minnesota, N.A., which encumbered the property, and assumption of approximately $340,000 of additional obligations of MCV. MCV and PKM relied on a fair market value appraisal of the property in determining the amount of such consideration. The transaction eliminates MCV indebtedness to Associated Bank Minnesota, N.A. in the amount of $2.5 million plus interest and improves MCV’s working capital and liquidity position. Of the net cash proceeds, $300,000 plus interest was applied to MCV’s indebtedness to PKM pursuant to a discretionary credit agreement secured by MCV’s assets, leaving a balance due PKM in the amount of approximately $943,000. As additional consideration for the transaction, MCV issued to PKM a five-year warrant for the purchase of 350,000 shares of common stock at an exercise price of $0.625 per share.
On November 27, 2001, MCV issued 1,500,000 units to the underwriter of its initial public offering. Each unit consists of one share of common stock and one redeemable Class A Warrant. Each Class A Warrant becomes exercisable and transferable separately from the common stock commencing May 20, 2003. Each Class A Warrant entitles the holder to purchase, at any time until November 20, 2004, one share of common stock at an exercise price of $6.50 per share, subject to customary anti-dilution adjustments. MCV may redeem the Class A Warrants for $0.01 per warrant at any time once they become exercisable, upon ten business days' written notice, if the closing price of MCV's common stock or units exceeds $8.50, subject to customary anti-dilution adjustments, for any ten consecutive trading days before such notice. In connection with MCV's initial public offering, the Reporting Person used personal funds to purchase 100,000 units from the underwriter at a price of $4.50 per unit, for an aggregate consideration of $450,000. On June 28, 2002, the Reporting Person's spouse used personal funds to purchase 4,500 units on the open market for $1.30 per unit.
The Reporting Person purchased 1,367,580 of the shares reported herein using personal funds. Such transactions took place between August 14, 1992, and May 4, 2001, at prices between $1.00 and $5.00 per share. Gracon Contracting, Inc. purchased 120,000 of the shares reported herein using working capital. Such transaction took place on September 13, 2000, at a price of $2.50 per share.
In August 1999, MCV obtained a bank line of credit from Riverside Bank, which was subsequently acquired by Associated Bank Minnesota, N.A. The loan was extended to MCV on the condition that it be personally guaranteed by the Reporting Person. Under an agreement entered into by the Reporting Person and MCV on August 31, 1999, the Reporting Person

personally guaranteed such indebtedness. To induce the Reporting Person to guarantee such indebtedness, MCV issued to the Reporting Person, on November 22, 1999 and December 6, 2000, warrants to purchase an aggregate of 100,000 shares of common stock exercisable at $2.00 per share. These warrants expire on November 19, 2004.
Between January 4, 1995 and August 15, 2002, MCV has granted options under MCV's 1993 Director Stock Option Plan to the Reporting Person to purchase shares of MCV common stock exercisable at prices between $0.83 and $5.00 per share in consideration of the Reporting Person's service on MCV's board of directors. Each option fully vests on the first anniversary of the date of grant. The exercise price of each option reflects the fair market value of MCV common stock on the date of grant. Of the options granted, the following options were outstanding at April 4, 2003:
• Option to purchase 7,000 shares at $5.00 per share granted on August 15, 1998, which expires on August 15, 2003.
• Option to purchase 6,000 shares at $5.00 per share granted on August 15, 1999, which expires on August 15, 2004.
• Option to purchase 1,000 shares at $5.00 per share granted on November 15, 1999, which expires on November 15, 2004.
• Option to purchase 7,000 shares at $2.50 per share granted on August 15, 2000, which expires on August 15, 2005.
• Option to purchase 7,000 shares at $4.50 per share granted on August 15, 2001, which expires on August 15, 2006.
• Option to purchase 7,000 shares at $0.83 per share granted on August 15, 2002, which expires on August 15, 2007.
With the exception of the last option listed, all of such options are exercisable within 60 days of April 4, 2003, and are included in the Reporting Person's beneficial ownership.

Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, the Reporting Person beneficially owned 2,524,580 shares of common stock, representing 28.8% of the class.
(b)	The Reporting Person has sole power to vote and to dispose of 2,515,580 shares of common stock. This number represents (a) 1,367,580 shares of common stock, (b) 100,000 units, each consisting of one share of common stock and one redeemable Class A Warrant to purchase one share of common stock, (c) 100,000 shares of common stock purchasable upon the exercise of warrants, (d) 28,000 shares of common stock purchasable upon the exercise of options, (e) 700,000 shares of common stock purchasable by PKM Properties, LLC, an entity owned by the Reporting Person, upon the exercise of warrants, and (f) 120,000 shares of common stock with Gracon Contracting, Inc., an entity owned by the Reporting Person. The Reporting Person shares the power to vote and to dispose of 4,500 units, each consisting of one share of common stock and one redeemable Class A Warrant to purchase one share of common stock, with the Reporting Person's spouse. Gracon Contracting, Inc., a Minnesota corporation, owns and operates a medical clinic building in Minneapolis, Minnesota. The business address of Gracon Contracting, Inc. is 606 24^th Avenue South, Suite B12, Minneapolis, Minnesota 55454.

	PKM Properties, LLC, a Minnesota limited liability company, owns certain real estate. The business address of PKM Properties, LLC is c/o Gracon Contracting, Inc., 606 24th Avenue South, Suite B12, Minneapolis, Minnesota 55454.
(c)	See Item 3.
(d)	The Reporting Person knows of no person who has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the shares reported herein.
(e)	Not applicable

Item 7.	Material to be Filed as Exhibits.
	See Exhibit Index.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	April 14, 2003
	Date
	/s/ Paul K. Miller
	Signature
	Paul K. Miller/Director MedicalCV, Inc.
	Name/Title

EXHIBIT INDEX

Exhibit 1		Form of Escrow Agreement by and among MedicalCV, Inc., Paul K. Miller, Adel A. Mikhail, Ph.D., Richard A. DeWall, M.D., Blair P. Mowery, Salvador Mercé Cervelló, Allan R. Seck, Norman Dann, Ronald Bosrock, George M. Wettstaedt, Gene E. Stobbs, Shelley Johnson, Salvador Mercé Vives, Mercé V. Electromedicina S.L., Associated Bank Minnesota and the Commissioner of Commerce for the State of Minnesota.*
Exhibit 2		1993 Director Stock Option Plan (incorporated by reference to MedicalCV, Inc.’s Registration Statement on Form SB-2, filed on August 31, 2001 (File No. 333-68884)).
Exhibit 3		Warrant Agreement to purchase 50,000 shares of common stock by and between MedicalCV, Inc. and Paul K. Miller, dated November 22, 1999 (incorporated by reference to MedicalCV, Inc.’s Registration Statement on Form SB-2, filed on August 31, 2001 (File No. 333-68884)).
Exhibit 4		Warrant Agreement to purchase 50,000 shares of common stock by and between MedicalCV, Inc. and Paul K. Miller, dated December 6, 2000 (incorporated by reference to MedicalCV, Inc.’s Registration Statement on Form SB-2, filed on August 31, 2001 (File No. 333-68884)).
Exhibit 5		Warrant Agreement to purchase 350,000 shares of common stock issued by MedicalCV,Inc. to PKM Properties, LLC, dated January 17, 2003.
Exhibit 6		Warrant Agreement to purchase 350,000 shares of common stock issued by MedicalCV,Inc. to PKM Properties, LLC, dated April 4, 2003.

________________

* Previously filed.

EX-5 3 j9438_ex5.htm EX-5

EXHIBIT 5

WARRANT

To Purchase 350,000 Shares of

Common Stock

MEDICALCV, INC.

This Warrant and the securities issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933 (the “Securities Act”) or under any state securities or “Blue Sky” laws (“Blue Sky Laws”). No transfer, sale, assignment, pledge, hypothecation or other disposition of this Warrant or the securities issuable upon exercise of this Warrant or any interest therein may be made except (a) pursuant to an effective registration statement under the Securities Act and any applicable Blue Sky Laws or (b) if the Company has been furnished with an opinion of counsel for the holder, which opinion and counsel shall be reasonably satisfactory to the Company, to the effect that no registration is required because of the availability of an exemption from registration under the Securities Act and applicable Blue Sky Laws.

THIS CERTIFIES THAT, for good and valuable consideration, PKM PROPERTIES, LLC a Minnesota limited liability company (“PKM Properties”) or its registered assigns, is entitled to subscribe for and purchase from MedicalCV, Inc., a Minnesota corporation (the “Company”), at any time to and including the date that is five (5) years after the date hereof. Three Hundred Fifty Thousand (350,000) fully paid and nonassessable shares of the Common Stock of the Company at the price of $0.596 per share (the “Warrant Exercise Price”), subject to the antidilution provisions of this Warrant. The shares which may be acquired upon exercise of this Warrant are referred to herein as the “Warrant Shares.” As used herein, the term “Holder” means PKM Properties, any party who acquires all or a part of this Warrant as a registered transferee of PKM Properties, or any record holder or holders of the Warrant Shares issued upon exercise, whether in whole or in part, of the Warrant; the term “Common Stock” means the Company’s Common Stock, $.01 par value.

This Warrant is subject to the following provisions, terms and conditions:

1. Exercise; Conversion Right; Transferability

(a) The rights represented by this Warrant may be exercised by the Holder hereof at any time, for a period of five (5) years commencing on the date hereof, in whole or in part (but not as to a fractional share of Common Stock), by written notice of exercise (in the form attached hereto) delivered to the Company at the principal office of the Company prior to the expiration of this

Warrant and accompanied or preceded by the surrender of this Warrant along with a check in payment of the Warrant Exercise Price for such shares.

(b) Subject to the restrictions on transfer of this Warrant or the Warrant Shares set forth herein, the Holder of this Warrant shall have the right to require the Company to convert this Warrant (the “Conversion Right’) at any time after the date hereof and prior to its expiration into shares of Common Stock as provided for in Sections 1(b) through 1(d) hereof. Upon exercise of the Conversion Right, the Company shall deliver to the Holder (without payment by the Holder of any Warrant Exercise Price) that number of shares of Company Common Stock equal to the quotient obtained by dividing (i) the value of the Warrant at the time the Conversion Right is exercised (determined by subtracting the aggregate Warrant Exercise Price for the Warrant Shares in effect immediately prior to the exercise of the Conversion Right from the aggregate Fair Market Value (as defined in Section 10 hereof) for the Warrant Shares immediately prior to the exercise of the Conversion Right) by (ii) the Fair Market Value of one share of Common Stock immediately prior to the exercise of the Conversion Right.

(c) The Conversion Right may be exercised by the Holder, at any time or from time to time, after the date hereof and prior to its expiration, on any business day by delivering a written notice in the form attached hereto (the “Conversion Notice”) to the Company at the offices of the Company exercising the Conversion Right and specifying (i) the total number of shares of Common Stock the Holder will purchase pursuant to such conversion and (ii) a place and date not less than one or more than 20 business days from the date of the Conversion Notice for the closing of such purchase.

(d) At any closing under Section 1(c) hereof, (i) the Holder will surrender the Warrant, (ii) the Company will deliver to the Holder a certificate or certificates for the number of shares of Common Stock issuable upon such conversion, together with cash, in lieu of any fraction of a share, and (iii) the Company will deliver to the Holder a new warrant representing the number of shares, if any, with respect to which the Warrant shall not have been exercised.

(e) Subject to the provisions of Section 7 hereof, this Warrant shall be fully transferable, in whole or in part; provided that this Warrant shall be transferable only on the books of the Company by the Holder in person, or by duly authorized attorney, on surrender of the Warrant, properly assigned.

2. Exchange and Replacement. Subject to Sections 1 and 7 hereof, this Warrant is exchangeable upon the surrender hereof by the Holder to the Company at its office for new Warrants of like tenor and date representing in the aggregate the right to purchase the number of Warrant Shares purchasable hereunder, each of such new Warrants to represent the right to purchase such number of Warrant Shares (not to exceed the aggregate total number purchasable hereunder) as shall be designated by the Holder at the time of such surrender. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and, in case of loss, theft or destruction, of indemnity reasonably satisfactory to it, and upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor, in lieu of this Warrant. This Warrant shall be promptly canceled by the Company upon the surrender hereof in connection with any exchange or replacement. The

Company shall pay all expenses, taxes (other than stock transfer taxes), and other charges incurred by it in connection with the preparation, execution, and delivery of Warrants pursuant to this Section 2.

3. Issuance of the Warrant Shares.

(a) The Company agrees that the shares of Common Stock purchased upon exercise of this Warrant shall be and are deemed to be issued to the Holder as of the close of business on the date on which this Warrant shall have been surrendered and the payment made for such Warrant Shares as aforesaid. Subject to the provisions of paragraph (b) of this Section 3, certificates for the Warrant Shares so purchased shall be delivered to the Holder within a reasonable time, not exceeding fifteen (15) days after the rights represented by this Warrant shall have been so exercised, and, unless this Warrant has expired, a new Warrant representing the right to purchase the number of Warrant Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be delivered to the Holder within such time.

(b) Notwithstanding the foregoing, the Company shall not be required to deliver any certificate for Warrant Shares upon exercise of this Warrant except in accordance with exemptions from the applicable securities registration requirements or registrations under applicable securities laws. Nothing herein, however, shall obligate the Company to effect registrations under federal or state securities laws, except as provided in Section 9. If registrations are not in effect and if exemptions are not available when the Holder seeks to exercise the Warrant, the Warrant exercise period will be extended, if need be, to prevent the Warrant from expiring, until such time as either registrations become effective or exemptions are available, and the Warrant shall then remain exercisable for a period of at least 30 calendar days from the date the Company delivers to the Holder written notice of the availability of such registrations or exemptions. The Holder agrees to execute such documents and make such representations, warranties, and agreements as may be required solely to comply with the exemptions relied upon by the Company, or the registrations made, for the issuance of the Warrant Shares.

4. Covenants of the Company. The Company covenants and agrees that all Warrant Shares will, upon issuance, be duly authorized and issued, fully paid, nonassessable, and free from all taxes, liens, and charges with respect to the issuance thereof. The Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant.

5. Antidilution Adjustments. The provisions of this Warrant are subject to adjustment as provided in this Section 5; provided that no adjustment shall be made pursuant to this Section 5 which has the effect of duplicating any adjustment made pursuant to the Articles of Incorporation of the Company or any Certificate of Designation thereto, if any.

(a) The Warrant Exercise Price shall be adjusted from time to time such that in case the Company shall hereafter:

(i) pay any dividends on any class of stock of the Company payable in Common Stock or securities convertible into Common Stock;

(ii) subdivide its then outstanding shares of Common Stock into a greater number of shares; or

(iii) combine outstanding shares of Common Stock, by reclassification or otherwise;

then, in any such event, the Warrant Exercise Price in effect immediately prior to such event shall (until adjusted again pursuant hereto) be adjusted immediately after such event to a price (calculated to the nearest full cent) determined by dividing (A) the number of shares of Common Stock outstanding immediately prior to such event, multiplied by the then existing Warrant Exercise Price, by (B) the total number of shares of Common Stock outstanding immediately after such event (including in each case the maximum number of shares of Common Stock issuable in respect of any securities convertible into Common Stock), and the resulting quotient shall be the adjusted Warrant Exercise Price per share. An adjustment made pursuant to this subsection shall become effective immediately after the record date in the case of a dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification. If, in connection with an adjustment made pursuant to this subsection or otherwise, the Holder of any Warrant thereafter surrendered for exercise shall become entitled to receive shares of two or more classes of capital stock or shares of Common Stock and other capital stock of the Company, the Board of Directors (whose determination shall be conclusive) shall determine the allocation of the adjusted Warrant Exercise Price between or among shares of such classes of capital stock or shares of Common Stock and other capital stock. All calculations under this subsection shall be made to the nearest cent or to the nearest 1/100 of a share, as the case may be. In the event that at any time, in connection with an adjustment made pursuant to this subsection or otherwise, the Holder of any Warrant thereafter surrendered for exercise shall become entitled to receive any shares of the Company other than shares of Common Stock, thereafter the Warrant Exercise Price of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to Common Stock contained in this Section.

(b) Upon each adjustment of the Warrant Exercise Price pursuant to Section 5(a) above, the Holder of each Warrant shall thereafter (until another such adjustment) be entitled to purchase at the adjusted Warrant Exercise Price the number of shares, calculated to the nearest full share, obtained by multiplying the number of shares specified in such Warrant (as adjusted as a result of all adjustments in the Warrant Exercise Price in effect prior to such adjustment) by the Warrant Exercise Price in effect prior to such adjustment and dividing the product so obtained by the adjusted Warrant Exercise Price.

then outstanding shall have the right thereafter to convert such Warrant into the kind and amount of shares of stock and other securities and property which the Holder would have owned or have been entitled to receive immediately after such consolidation, merger, statutory exchange, sale, or conveyance had such Warrant been converted immediately prior to the effective date of such consolidation, merger, statutory exchange, sale, or conveyance. The Company shall give written notice, by first–class mail, postage prepaid, addressed to the Holder as shown on the books of the Company, of the date on which such consolidation, merger, sale, conveyance or statutory exchange shall take place. Such notice shall also specify the date as of which the Holder shall be entitled to exchange such Holder’s Warrant Shares (if any) for securities or other property deliverable upon such consolidation, merger, sale, conveyance or statutory exchange, as the case may be. Such written notice shall be at least 20 days prior to the action in question. In any such case, if deemed necessary by the Company’s Board of Directors to fairly protect the rights of the Holders stated herein, appropriate adjustment shall be made in the application of the provisions set forth in this Section with respect to the rights and interests thereafter of any Holders of the Warrant, to the end that the provisions set forth in this Section shall thereafter correspondingly be made applicable, as nearly as may reasonably be, in relation to any shares of stock and other securities and property thereafter deliverable on the exercise of the Warrant. The provisions of this subsection shall similarly apply to successive consolidations, mergers, statutory exchanges, sales or conveyances.

(d) Upon any adjustment of the Warrant Exercise Price, then and in each such case, the Company shall give written notice thereof, by first–class mail, postage prepaid, addressed to the Holder as shown on the books of the Company, which notice shall state the Warrant Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares of Common Stock purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.

6. No Voting Rights. This Warrant shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company.

7. Notice of Transfer of Warrant or Resale of the Warrant Shares.

(a) The Holder, by acceptance hereof, agrees to give written notice to the Company before transferring this Warrant or transferring any Warrant Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly upon receiving such written notice, the Company shall present copies thereof to the Company’s counsel and to counsel to the original purchaser of this Warrant. If in the opinion of each such counsel the proposed transfer may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly as practicable, shall notify the Holder of such opinion, whereupon the Holder shall be entitled to transfer this Warrant or to dispose of Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by the Holder to the Company; provided that an appropriate legend may be endorsed on this Warrant or the certificates for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act of 1933, as amended (the “Securities Act”) and applicable state securities laws; and provided further that the prospective transferee or purchaser shall execute such documents and make such representations, warranties, and agreements

as may be required solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

(b) If in the opinion of either of the counsel referred to in this Section 7, the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares the Company shall promptly give written notice thereof to the Holder, and the Holder will limit its activities in respect to such transfer or disposition as, in the opinion of both such counsel, are permitted by law.

8. Fractional Shares. Fractional shares shall not be issued upon the exercise of this Warrant, but in any case where the Holder would, except for the provisions of this Section, be entitled under the terms hereof to receive a fractional share, the Company shall, upon the exercise of this Warrant for the largest number of whole shares then called for, pay a sum in cash equal to the sum of (a) the excess, if any, of the Fair Market Value of such fractional share over the proportional part of the Warrant Exercise Price represented by such fractional share, plus (b) the proportional part of the Warrant Exercise Price, if paid by the Holder, represented by such fractional share.

9. Registration Rights.

(a) If the Company at any time until two (2) years after complete exercise or expiration of this Warrant proposes to register under the Securities Act (except by a Form S–4 or Form S–8 Registration Statement or any successor forms thereto) any of its equity securities, it will give written notice to all Holders of this Warrant, any Warrants issued pursuant to Section 2 and/or Section 3(a) hereof, and any Warrant Shares of its intention to do so and, on the written request of any such Holder given within twenty (20) days after receipt of any such notice (which request shall specify the Warrant Shares intended to be sold or disposed of by such Holder and describe the nature of any proposed sale or other disposition thereof), the Company will use its best efforts to cause all such Warrant Shares, the Holders of which shall have requested the registration or qualification thereof, to be included in such registration statement proposed to be filed by the Company; provided that:

(i) if a greater number of Warrant Shares is offered for participation in the proposed offering than in the reasonable opinion of the managing underwriter of the proposed offering can be accommodated without adversely affecting the proposed offering, then the amount of Warrant Shares proposed to be offered by such Holders for registration, as well as the number of securities of any other selling shareholders participating in the registration, shall be proportionately reduced to a number deemed satisfactory by the managing underwriter

(ii) the Company may, at its sole discretion and without the consent of any holder of the Warrant Shares, withdraw such registration statement and abandon the proposed offering in which any such holder had requested to participate;

(iii) if the offering to which the registration statement relates is to be distributed by or through an underwriter, each holder of the Warrant Shares shall agree, as a condition

to the inclusion of such holder’s securities in such registration, to sell securities held by such holder through such underwriter on the same terms and conditions as the underwriter agrees to sell securities on behalf of the Company and not to sell, transfer, pledge, assign or otherwise dispose of the Warrant Shares of the Company not sold by such holder in such offering for such period (up to 180 days after the effective date of the registration statement) as may be required by the underwriter;

(iv) the Company shall not be obligated to include any Warrant Shares in any such registration for any Holder who is able to sell all of the Warrant Shares in a single transaction pursuant to Rule 144 under the Securities Act (or any other similar rule or regulation) during the three–month period beginning on the date such notice is received by such holder, calculated as of the date of such receipt.

(b) Further, on a one–time basis only, at any time until two (2) years after complete exercise or expiration of this Warrant, upon request by the Holder or Holders of a majority in interest of this Warrant, of any Warrants issued pursuant to Section 2 and/or Section 3(a) hereof, and of any Warrant Shares, the Company will promptly take all necessary steps to register or qualify, under the Securities Act and the securities laws of such states as the Holders may reasonably request, such number of Warrant Shares issued and to be issued upon conversion of the Warrants requested by such Holders in their request to the Company; provided that the Company shall not be obligated to include any Warrant Shares in any such registration for any Holder who is able to sell all of the Warrant Shares in a single transaction pursuant to Rule 144 under the Securities Act (or any other similar rule or regulation) during the three–month period beginning on the date such notice is received by such holder, calculated as of the date of such receipt. The Company shall keep effective and maintain any registration, qualification, notification, or approval specified in this Paragraph (b) for such period as may be reasonably necessary for such Holder or Holders of such Warrant Shares to dispose thereof and from time to time shall amend or supplement the prospectus used in connection therewith to the extent necessary in order to comply with applicable law.

(c) Upon the exercise of registration rights pursuant to this Section 9, Holder agrees to supply the Company with such information as may be required by the Company to register or qualify the shares to be registered.

(d) With respect to each inclusion of securities in a registration statement pursuant to this Section 9, the Company shall bear the following fees, costs, and expenses: all registration, filing and NASD fees, printing expenses, fees and disbursements of counsel and accountants for the Company, fees and disbursements of counsel for the underwriter or underwriters of such securities (if the Company is required to bear such fees and disbursements), all internal expenses, and legal fees and disbursements and other expenses of complying with state securities laws of any jurisdictions in which the securities to be offered are to be registered or qualified. Fees and disbursements of special counsel and accountants for the selling Holders, underwriting discounts and commissions, and transfer taxes for selling Holders and any other expenses relating to the sale of securities by the selling Holders not expressly included above shall be borne by the selling Holders.

(e) The Company hereby indemnifies each of the Holders of this Warrant and of any Warrant Shares, and the officers and directors, if any, who control such Holders, within the meaning of Section 15 of the Securities Act, against all losses, claims, damages, and liabilities caused by (i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or Prospectus (and as amended or supplemented if the Company shall have furnished any amendments thereof or supplements thereto), any Preliminary Prospectus or any state securities law filings; (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading except insofar as such losses, claims, damages, or liabilities are caused by any untrue statement or omission contained in information furnished in writing to the Company by such Holder expressly for use therein; and each such Holder by its acceptance hereof severally agrees that it will indemnify and hold harmless the Company, each of its officers who signs such Registration Statement, each underwriter of the Common Stock so registered, and each person, if any, who controls the Company or such underwriter, within the meaning of Section 15 of the Securities Act, with respect to losses, claims, damages, or liabilities which are caused by any untrue statement or omission contained in information furnished in writing to the Company by such Holder expressly for use therein.

10. Fair Market Value. Fair Market Value of a share of Common Stock as of a particular date (the “Determination Date”) shall mean:

(a) If the Company’s Common Stock is traded on an exchange or is listed on the Nasdaq National Market or the Nasdaq SmallCap Market, then the average closing or last sale prices, respectively, reported for the ten (10) business days immediately preceding the Determination Date; or

(b) If the Company’s Common Stock is not traded on an exchange or listed on the Nasdaq National Market or the Nasdaq SmallCap Market but is listed on the OTC Bulletin Board, the National Quotation Bureau, the BBX, or any comparable reporting service, then the average of the closing bid and ask prices reported for the ten (10) business days immediately preceding the Determination Date; or

(c) If the Company’s Common Stock is not listed on an exchange, on the Nasdaq National Market, the Nasdaq SmallCap Market, the OTC Bulletin Board, the National Quotation Bureau, the BBX, or any comparable reporting service, then the fair market value as determined in good faith by the Board of Directors of the Company.

[signature page follows]

IN WITNESS WHEREOF, MedicalCV, Inc. has caused this Warrant to be signed by its duly authorized officer and this Warrant to be dated January 17, 2003.

MEDICALCV, INC.

By	/s/ Blair P. Mowery
	Its	Chief Executive Officer

NOTICE OF EXERCISE OF WARRANT

(To be signed upon the exercise of the Warrant)

The undersigned hereby irrevocably elects to exercise the attached Warrant to purchase, for cash, ________________ of the shares of Common Stock issuable upon the exercise of such Warrant, and requests that certificates for the shares of Common Stock (together with a new Warrant to purchase the number of shares, if any, with respect to which this Warrant is not exercised) be issued in the name and address set forth below.

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

* The signature on the Notice of Exercise of Warrant must correspond to the name as written upon the face of the Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, PLEASE indicate your position(s) and title(s) with such entity.

CONVERSION NOTICE

(To be signed upon exercise of Warrant pursuant to Sections 1(b) through 1(d))

The undersigned hereby irrevocably elects to exercise the Conversion Right provided in Sections 1(b) through 1(d) of the within Warrant for, and to acquire thereunder, ________ shares of Common Stock. If said number of shares shall not be all the shares purchasable under the within Warrant, a new Warrant is to be issued in the name of said undersigned for the balance remaining of the shares purchasable thereunder rounded up to the next higher number of shares.

Please issue a certificate or certificates for the shares of Common Stock in the name set forth below.

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

* The signature on the Conversion Notice must correspond to the name as written upon the face of the Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, PLEASE indicate your position(s) and title(s) with such entity.

ASSIGNMENT OF WARRANT

(To be signed only upon authorized transfer of the Warrant)

FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers unto ______________ the right to purchase ________ shares of Common Stock of MedicalCV, Inc., to which the within Warrant relates and appoints ________________, as attorney–in–fact, to transfer said right on the books of MedicalCV, Inc. with full power of substitution in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

* The signature on the Assignment of Warrant must correspond to the name as written upon the face of the Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, PLEASE indicate your positions) and title(s) with such entity.

EX-6 4 j9438_ex6.htm EX-6

EXHIBIT 6

WARRANT

To Purchase 350,000 Shares of

Common Stock

MEDICALCV, INC.

THIS CERTIFIES THAT, for good and valuable consideration, PKM PROPERTIES, LLC a Minnesota limited liability company (“PKM Properties”) or its registered assigns, is entitled to subscribe for and purchase from MedicalCV, Inc., a Minnesota corporation (the “Company”), at any time to and including the date that is five (5) years after the date hereof. Three Hundred Fifty Thousand (350,000) fully paid and nonassessable shares of the Common Stock of the Company at the price of $)0.625 per share (the “Warrant Exercise Price”), subject to the antidilution provisions of this Warrant. The shares which may be acquired upon exercise of this Warrant are referred to herein as the “Warrant Shares.” As used herein, the term “Holder” means PKM Properties, any party who acquires all or a part of this Warrant as a registered transferee of PKM Properties, or any record holder or holders of the Warrant Shares issued upon exercise, whether in whole or in part, of the Warrant; the term “Common Stock” means the Company’s Common Stock, $.01 par value.

This Warrant is subject to the following provisions, terms and conditions:

1. Exercise; Conversion Right; Transferability

(b) Subject to the restrictions on transfer of this Warrant or the Warrant Shares set forth herein, the Holder of this Warrant shall have the right to require the Company to convert

this Warrant (the “Conversion Right’) at any time after the date hereof and prior to its expiration into shares of Common Stock as provided for in Sections 1(b) through 1(d) hereof. Upon exercise of the Conversion Right, the Company shall deliver to the Holder (without payment by the Holder of any Warrant Exercise Price) that number of shares of Company Common Stock equal to the quotient obtained by dividing (i) the value of the Warrant at the time the Conversion Right is exercised (determined by subtracting the aggregate Warrant Exercise Price for the Warrant Shares in effect immediately prior to the exercise of the Conversion Right from the aggregate Fair Market Value (as defined in Section 10 hereof) for the Warrant Shares immediately prior to the exercise of the Conversion Right) by (ii) the Fair Market Value of one share of Common Stock immediately prior to the exercise of the Conversion Right.

3. Issuance of the Warrant Shares.

(a) The Warrant Exercise Price shall be adjusted from time to time such that in case the Company shall hereafter:

(i) pay any dividends on any class of stock of the Company payable in Common Stock or securities convertible into Common Stock;

(ii) subdivide its then outstanding shares of Common Stock into a greater number of shares; or

(iii) combine outstanding shares of Common Stock, by reclassification or otherwise;

(c) In case of any consolidation or merger to which the Company is a party other than a merger or consolidation in which the Company is the continuing corporation, or in case of any sale or conveyance to another corporation of all or substantially all of the assets of the Company, as an entirety, or in the case of any statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company), there shall be no adjustment under subsection (a) of this Section above but the Holder of each Warrant then outstanding shall have the right thereafter to convert such Warrant into the kind and amount of shares of stock and other securities and property which the Holder would have owned or have been entitled to receive immediately after such consolidation, merger, statutory exchange, sale, or conveyance had such Warrant been converted immediately prior to the effective date of such consolidation, merger, statutory exchange, sale, or conveyance. The Company shall give written

notice, by first–class mail, postage prepaid, addressed to the Holder as shown on the books of the Company, of the date on which such consolidation, merger, sale, conveyance or statutory exchange shall take place. Such notice shall also specify the date as of which the Holder shall be entitled to exchange such Holder’s Warrant Shares (if any) for securities or other property deliverable upon such consolidation, merger, sale, conveyance or statutory exchange, as the case may be. Such written notice shall be at least 20 days prior to the action in question. In any such case, if deemed necessary by the Company’s Board of Directors to fairly protect the rights of the Holders stated herein, appropriate adjustment shall be made in the application of the provisions set forth in this Section with respect to the rights and interests thereafter of any Holders of the Warrant, to the end that the provisions set forth in this Section shall thereafter correspondingly be made applicable, as nearly as may reasonably be, in relation to any shares of stock and other securities and property thereafter deliverable on the exercise of the Warrant. The provisions of this subsection shall similarly apply to successive consolidations, mergers, statutory exchanges, sales or conveyances.

6. No Voting Rights. This Warrant shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company.

7. Notice of Transfer of Warrant or Resale of the Warrant Shares.

(b) If in the opinion of either of the counsel referred to in this Section 7, the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given

pursuant to this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares the Company shall promptly give written notice thereof to the Holder, and the Holder will limit its activities in respect to such transfer or disposition as, in the opinion of both such counsel, are permitted by law.

9. Registration Rights.

(iii) if the offering to which the registration statement relates is to be distributed by or through an underwriter, each holder of the Warrant Shares shall agree, as a condition to the inclusion of such holder’s securities in such registration, to sell securities held by such holder through such underwriter on the same terms and conditions as the underwriter agrees to sell securities on behalf of the Company and not to sell, transfer, pledge, assign or otherwise dispose of the Warrant Shares of the Company not sold by such holder in such

offering for such period (up to 180 days after the effective date of the registration statement) as may be required by the underwriter;

Statement or Prospectus (and as amended or supplemented if the Company shall have furnished any amendments thereof or supplements thereto), any Preliminary Prospectus or any state securities law filings; (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading except insofar as such losses, claims, damages, or liabilities are caused by any untrue statement or omission contained in information furnished in writing to the Company by such Holder expressly for use therein; and each such Holder by its acceptance hereof severally agrees that it will indemnify and hold harmless the Company, each of its officers who signs such Registration Statement, each underwriter of the Common Stock so registered, and each person, if any, who controls the Company or such underwriter, within the meaning of Section 15 of the Securities Act, with respect to losses, claims, damages, or liabilities which are caused by any untrue statement or omission contained in information furnished in writing to the Company by such Holder expressly for use therein.

10. Fair Market Value. Fair Market Value of a share of Common Stock as of a particular date (the “Determination Date”) shall mean:

[signature page follows]

IN WITNESS WHEREOF, MedicalCV, Inc. has caused this Warrant to be signed by its duly authorized officer and this Warrant to be dated April 4, 2003.

MEDICALCV, INC.

By	/s/ Blair P. Mowery
	Its	Chief Executive Officer

NOTICE OF EXERCISE OF WARRANT

(To be signed upon the exercise of the Warrant)

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

CONVERSION NOTICE

(To be signed upon exercise of Warrant pursuant to Sections 1(b) through 1(d))

Please issue a certificate or certificates for the shares of Common Stock in the name set forth below.

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

ASSIGNMENT OF WARRANT

(To be signed only upon authorized transfer of the Warrant)

Dated: __________________

	(Signature)


	(Name)


	(Address)


	(Social Security or Tax Ident. No.)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

Signature

INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS
THERETO FILED PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934
(Amendment No. 2)*